TNFRSF17 and Miyoshi myopathy: Recently, numerous BsAbs have been developed for MM treatment, with ideal tumor antigen targets including BCMA, G protein-coupled receptor 5D (GPRC5D), Fc receptor-like 5 (FCRL5), and CD38.